{'52WeekChange': 0.053590536,
 'SandP52WeekChange': 0.0644362,
 'address1': '10880 Wilshire Boulevard',
 'address2': 'Suite 2150',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.83,
 'askSize': 1400,
 'averageDailyVolume10Day': 696887,
 'averageVolume': 1052704,
 'averageVolume10days': 696887,
 'beta': 1.198319,
 'beta3Year': None,
 'bid': 9.6,
 'bidSize': 1400,
 'bookValue': 0.238,
 'category': None,
 'circulatingSupply': None,
 'city': 'Los Angeles',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 9.99,
 'dayLow': 9.65,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -7.512,
 'enterpriseToRevenue': 1.813,
 'enterpriseValue': 406816832,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '424-248-6501',
 'fiftyDayAverage': 10.375143,
 'fiftyTwoWeekHigh': 15,
 'fiftyTwoWeekLow': 5.5,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 29250095,
 'forwardEps': -0.6,
 'forwardPE': -16.383333,
 'fromCurrency': None,
 'fullTimeEmployees': 269,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.1159,
 'heldPercentInstitutions': 0.88808,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/pumabiotechnology.com',
 'longBusinessSummary': 'Puma Biotechnology, Inc., a biopharmaceutical '
                        'company, focuses on the development and '
                        'commercialization of products to enhance cancer care. '
                        'Its drug candidates include PB272 neratinib (oral) '
                        'for the treatment of early stage breast cancer, '
                        'metastatic breast cancer, non-small cell lung cancer, '
                        'HER2 mutation-positive solid tumors, and HER2-mutated '
                        'non-amplified breast cancer; and PB272 neratinib '
                        '(intravenous). The company also develops PB357, an '
                        'orally administered agent that is an irreversible '
                        'tyrosine kinase inhibitor that blocks signal '
                        'transduction through the epidermal growth factor '
                        'receptors, HER1, HER2, and HER4. It has a license '
                        'agreement with Pfizer, Inc. for the development, '
                        'manufacture, and commercialization of PB272 neratinib '
                        '(oral), PB272 neratinib (intravenous), PB357, and '
                        'certain related compounds. Puma Biotechnology, Inc. '
                        'was founded in 2010 and is headquartered in Los '
                        'Angeles, California.',
 'longName': 'Puma Biotechnology, Inc.',
 'market': 'us_market',
 'marketCap': 386952064,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_128739842',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -82441000,
 'nextFiscalYearEnd': 1640908800,
 'open': 9.88,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.04,
 'phone': '424-248-6500',
 'previousClose': 9.96,
 'priceHint': 2,
 'priceToBook': 41.30252,
 'priceToSalesTrailing12Months': 1.7243085,
 'profitMargins': -0.36737,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 9.99,
 'regularMarketDayLow': 9.65,
 'regularMarketOpen': 9.88,
 'regularMarketPreviousClose': 9.96,
 'regularMarketPrice': 9.88,
 'regularMarketVolume': 650500,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 39364400,
 'sharesPercentSharesOut': 0.1732,
 'sharesShort': 6816273,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 7442145,
 'shortName': 'Puma Biotechnology Inc',
 'shortPercentOfFloat': 0.22600001,
 'shortRatio': 6.11,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'PBYI',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.117,
 'twoHundredDayAverage': 10.098561,
 'volume': 650500,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.pumabiotechnology.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '90024'}